Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVARTIS AG : UBS keeps its Buy rating

10/14/2020 | 06:41am EST

In his latest research note, analyst Laura Sutcliffe confirms his positive recommendation. The broker UBS is keeping its Buy rating. The target price is unchanged at CHF 98.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG -1.22% 80.92 Delayed Quote.-10.86%
UBS GROUP AG 0.35% 12.935 Delayed Quote.5.44%
All news about NOVARTIS AG
12/01NOVARTIS : Genentech Get Expanded FDA OK of Xolair for Nasal Polyps
DJ
11/29Swiss firms narrowly avoid 'Responsible Business' liability as vote divides n..
RE
11/27NOVARTIS AG : Barclays reaffirms its Sell rating
MD
11/26Business rights or human rights? Swiss vote shines spotlight on companies
RE
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/25NOVARTIS AG : Bryan Garnier maintains a Buy rating
MD
11/25NOVARTIS AG : UBS reiterates its Buy rating
MD
11/25NOVARTIS AG : Goldman Sachs remains its Buy rating
MD
11/24GLOBAL MARKETS LIVE: Tesla, Best Buy, Qantas…
11/24NOVARTIS AG : Goldman Sachs reaffirms its Buy rating
MD
More news
Financials (USD)
Sales 2020 49 423 M - -
Net income 2020 8 322 M - -
Net Debt 2020 19 271 M - -
P/E ratio 2020 24,8x
Yield 2020 3,48%
Capitalization 207 B 207 B -
EV / Sales 2020 4,57x
EV / Sales 2021 4,21x
Nbr of Employees 110 000
Free-Float 86,9%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 105,85 $
Last Close Price 90,82 $
Spread / Highest target 55,0%
Spread / Average Target 16,5%
Spread / Lowest Target -28,7%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-10.86%206 585
JOHNSON & JOHNSON2.15%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.8.00%226 783
MERCK & CO., INC.-10.03%207 033
ABBVIE INC.18.58%185 357